Perspective · 17 Mar 2025
Conference abstractPublished 11 Sep 2024
Harnessing AI for Pharmaceutical Innovation: Navigating the Current Landscape and Future Directions
OKRA.ai’s founder, A Renowned ML scientist, Horsham, West Sussex, United Kingdom
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In the rapidly evolving landscape of pharmaceuticals, the integration of Artificial Intelligence (AI) stands as a pivotal force shaping the industry’s trajectory. Since the acquisition of OKRA by EPG, our company has been at the forefront of this transformative journey. However, the urgency to invest in AI for life sciences has never been clearer, with numerous companies already leveraging AI to drive innovation across healthcare sectors. My keynote delves into the imperative need for pharmaceutical companies to embrace AI technologies now and explores why many are lagging behind. We examine recent developments, such as the groundbreaking advancements, including the noteworthy achievement of Generative AI passing medical licensing exams, underscoring AI’s potential within healthcare. Moreover, we scrutinize industry pioneers, who have revolutionized patient engagement and personalized care through interactive AI platforms. These examples highlight the tangible benefits and transformative power of AI in healthcare delivery. Furthermore, we analyze the competitive landscape, where companies are rapidly deploying AI solutions to streamline processes, enhance product launches, and analyze patient data with unprecedented efficiency. From AI-powered tools for global product launches to platforms offering personalized patient insights, the race to harness AI in pharmaceuticals is palpable.I will provide an overview of recent successful use cases. However, amidst these advancements, many companies find themselves navigating uncharted waters, lacking a clear direction for innovation. The absence of a cohesive strategy risks stalling progress and stifling motivation. Conclusion: I will highlight in my talk the critical need for pharmaceutical companies to not only embrace AI but also to strategize effectively to navigate the complexities of the evolving landscape. The conference will provide a platform for insightful discussions on leveraging AI for pharmaceutical innovation and charting a course for future success.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Analytical Chemistry: Open Access.
Commentary · 11 Mar 2025
Advancements in Spectroscopic Techniques for Quality Assurance in Pharmaceutical Drug Analysis
Commentary · 11 Mar 2025
LC-MS/MS Methods for Quantifying Drugs and Metabolites in Plasma
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Analytical Chemistry: Open Access
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Loubna Bouarfa”
